Adjuvant and salvage radiotherapy after neoadjuvant therapy and radical prostatectomy for high‐risk localized prostate cancer
The Prostate · 2024
DOI: 10.1002/pros.24653 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, 2024. Verfasst von Praful Ravi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Janssen Pharmaceutics, Medivation/Astellas, GSK, and AstraZeneca.
Abstract (Originalsprache)
Background
We sought to describe patterns of delivery of adjuvant (aRT) and salvage RT (sRT) in patients who underwent RP after receiving neoadjuvant androgen receptor pathway inhibitor (ARPI) before radical prostatectomy (RP) for high‐risk localized prostate cancer (HRLPC).
Methods
Two hundred eighteen patients treated on phase 2 neoadjuvant trials between 2006 and 2018 at two academic centers were evaluated. aRT and sRT were defined as receipt of RT with a PSA of ≤0.1 or >0.1 ng/mL, respectively. Primary outcomes were biochemical recurrence (BCR), defined as time from aRT/sRT to a PSA rising to >0.1 ng/mL, and metastasis‐free survival (MFS) after RT.
Results
Twenty‐three (11%) and 55 (25%) patients received aRT and sRT respectively. Median PSA at start of aRT and sRT was 0.01 and 0.16 ng/mL, and median duration from RP to RT was 5 and 14 months, respectively. All aRT patients had NCCN high‐risk disease, 30% were pN1 and 43% had positive surgical margins; 52% had prostate bed RT. Fifty‐one percent of sRT patients had biopsy Gleason 9–10, 29% were pT2 and 9% had positive surgical margins; 63% had RT to the prostate bed/pelvis. At a median follow‐up of 5.3 and 3.0 years after aRT and sRT, 3‐year freedom from BCR was 55% and 47%, and 3‐year MFS was 56% and 53%, respectively. Conclusions aRT was infrequently used in patients who received neoadjuvant ARPI before RP for HRLPC. Outcomes of aRT and sRT were similar but generally poor. Studies evaluating intensified systemic therapy approaches with postoperative RT in this high‐risk population are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- Department of Urology, KU Leuven, Leuven, Belgium.
- Department of Radiation Oncology, Brigham & Women's Hospital, Boston, Massachusetts, USA.
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
- Department of Urology, Brigham & Women's Hospital, Boston, Massachusetts, USA.
ORCID-Profile: Praful Ravi, Adam S Kibel
Förderung
- Janssen Pharmaceutics, Medivation/Astellas, GSK, and AstraZeneca
Zitieren
APA
Ravi, P., Kwak, L., Devlies, W., Xie, W., Chipidza, F., Yang, X., Bubley, G., Kaplan, I., Kibel, A. S., Nguyen, P., & Taplin, M. E. (2024). Adjuvant and salvage radiotherapy after neoadjuvant therapy and radical prostatectomy for high‐risk localized prostate cancer. The Prostate. https://doi.org/10.1002/pros.24653
Vancouver
Ravi P, Kwak L, Devlies W, Xie W, Chipidza F, Yang X, et al. Adjuvant and salvage radiotherapy after neoadjuvant therapy and radical prostatectomy for high‐risk localized prostate cancer. The Prostate. 2024. doi:10.1002/pros.24653
BibTeX
@article{Ravi2024,
author = {Ravi, Praful and Kwak, Lucia and Devlies, Wout and Xie, Wanling and Chipidza, Fallon and Yang, Xiaoyu and Bubley, Glenn and Kaplan, Irving and Kibel, Adam S and Nguyen, Paul and Taplin, Mary-Ellen},
title = {Adjuvant and salvage radiotherapy after neoadjuvant therapy and radical prostatectomy for high‐risk localized prostate cancer},
journal = {The Prostate},
year = {2024},
doi = {10.1002/pros.24653}
}
EUVIMED